Related references
Note: Only part of the references are listed.Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features
Hitoshi Dejima et al.
NATURE COMMUNICATIONS (2021)
Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
Diego Chowell et al.
NATURE MEDICINE (2019)
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
MHC-I Genotype Restricts the Oncogenic Mutational Landscape
Rachel Marty et al.
CELL (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
Immunotherapy in melanoma: Recent advances and future directions
C. Franklin et al.
EJSO (2017)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
RECIST 1.1-Update and clarification: From the RECIST committee
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
Targeting T Cell Co-receptors for Cancer Therapy
Margaret K. Callahan et al.
IMMUNITY (2016)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi et al.
LANCET ONCOLOGY (2015)
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes
Sachet A. Shukla et al.
NATURE BIOTECHNOLOGY (2015)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Melanoma genome sequencing reveals frequent PREX2 mutations
Michael F. Berger et al.
NATURE (2012)
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Bo Li et al.
BMC BIOINFORMATICS (2011)
NetMHCpan, a method for MHC class I binding prediction beyond humans
Ilka Hoof et al.
IMMUNOGENETICS (2009)
Enhanced functionality of CD4+CD25highFoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer
Junko Yokokawa et al.
CLINICAL CANCER RESEARCH (2008)
Share Paper
